Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):887-906. doi: 10.1158/1055-9965.EPI-15-1223. Epub 2016 Apr 6. Review.

PMID:
27197278
2.

Discrimination of Basal Cell Carcinoma from Normal Skin Tissue Using High-Resolution Magic Angle Spinning 1H NMR Spectroscopy.

Mun JH, Lee H, Yoon D, Kim BS, Kim MB, Kim S.

PLoS One. 2016 Mar 2;11(3):e0150328. doi: 10.1371/journal.pone.0150328. eCollection 2016.

3.

Response to Comments on "Magnetic Resonance Spectroscopy Identifies Neural Progenitor Cells in the Live Human Brain".

Djurić PM, Benveniste H, Wagshul ME, Henn F, Enikolopov G, Maletić-Savatić M.

Science. 2008 Aug 1;321(5889):640.

4.

Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer.

Thapar R, Titus MA.

Curr Metabolomics. 2014 Apr;2(1):53-69.

5.

Magnetic resonance in the detection of breast cancers of different histological types.

Mayrhofer RM, Ng HP, Putti TC, Kuchel PW.

Magn Reson Insights. 2013 Apr 30;6:33-49. doi: 10.4137/MRI.S10640. eCollection 2013. Review.

6.

A review of applications of metabolomics in cancer.

Beger RD.

Metabolites. 2013 Jul 5;3(3):552-74. doi: 10.3390/metabo3030552.

7.

The role of metabolic imaging in radiation therapy of prostate cancer.

Zhang VY, Westphalen A, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J.

NMR Biomed. 2014 Jan;27(1):100-11. doi: 10.1002/nbm.3007. Epub 2013 Aug 12. Review.

8.

HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.

Tripathi P, Somashekar BS, Ponnusamy M, Gursky A, Dailey S, Kunju P, Lee CT, Chinnaiyan AM, Rajendiran TM, Ramamoorthy A.

J Proteome Res. 2013 Jul 5;12(7):3519-28. doi: 10.1021/pr4004135. Epub 2013 Jun 18.

9.

1H-NMR based metabonomic profiling of human esophageal cancer tissue.

Wang L, Chen J, Chen L, Deng P, Bu Q, Xiang P, Li M, Lu W, Xu Y, Lin H, Wu T, Wang H, Hu J, Shao X, Cen X, Zhao YL.

Mol Cancer. 2013 Apr 4;12:25. doi: 10.1186/1476-4598-12-25.

10.

Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Spur EM, Decelle EA, Cheng LL.

Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S60-71. doi: 10.1007/s00259-013-2379-x. Epub 2013 Apr 3. Review.

11.

High-resolution magic angle spinning 1H MRS in prostate cancer.

Decelle EA, Cheng LL.

NMR Biomed. 2014 Jan;27(1):90-9. doi: 10.1002/nbm.2944. Epub 2013 Mar 26. Review.

12.

Markers of field cancerization: proposed clinical applications in prostate biopsies.

Trujillo KA, Jones AC, Griffith JK, Bisoffi M.

Prostate Cancer. 2012;2012:302894. doi: 10.1155/2012/302894. Epub 2012 May 14.

13.

Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery.

Denkert C, Bucher E, Hilvo M, Salek R, Orešič M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn O.

Genome Med. 2012 Apr 30;4(4):37.

14.

Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy.

Dittrich R, Kurth J, Decelle EA, DeFeo EM, Taupitz M, Wu S, Wu CL, McDougal WS, Cheng LL.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):278-82. doi: 10.1038/pcan.2011.70. Epub 2012 Jan 31.

15.

Application of magnetic-resonance-spectroscopy- based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma.

Jordan KW, Adkins CB, Cheng LL, Faquin WC.

Acta Cytol. 2011;55(6):584-9. doi: 10.1159/000333271. Epub 2011 Dec 9.

16.

Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.

Lodi A, Ronen SM.

PLoS One. 2011;6(10):e26155. doi: 10.1371/journal.pone.0026155. Epub 2011 Oct 12.

17.

Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues.

Somashekar BS, Kamarajan P, Danciu T, Kapila YL, Chinnaiyan AM, Rajendiran TM, Ramamoorthy A.

J Proteome Res. 2011 Nov 4;10(11):5232-41. doi: 10.1021/pr200800w. Epub 2011 Oct 18.

18.

Application of metabolomics to prostate cancer.

Trock BJ.

Urol Oncol. 2011 Sep-Oct;29(5):572-81. doi: 10.1016/j.urolonc.2011.08.002. Review.

19.

Magnetic resonance spectroscopy: a promising tool for the diagnostics of human prostate cancer?

Kurth J, Defeo E, Cheng LL.

Urol Oncol. 2011 Sep-Oct;29(5):562-71. doi: 10.1016/j.urolonc.2011.05.016. Review.

20.

Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.

Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J.

NMR Biomed. 2011 Jul;24(6):691-9. doi: 10.1002/nbm.1738.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk